College of Medical and Dental Sciences, 150183University of Birmingham, Birmingham, UK.
2379Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
Post Reprod Health. 2022 Jun;28(2):79-91. doi: 10.1177/20533691221097042. Epub 2022 May 23.
For women with menopause symptoms refractory to standard hormone replacement therapy (HRT) preparations, HRT implants offer an alternative. The primary objective of this study was to evaluate women's perceptions regarding efficacy, tolerability, satisfaction and safety of implant therapy.
A single centre service evaluation study performed at Birmingham Women's & Children's Foundation Hospital Trust. An anonymised semi-structured survey link was posted to all women ( = 397) recorded to have received HRT implant(s) at a tertiary Menopause clinic (May 1982 and Dec 2018). Women attending clinic (June 2020 to Sept 2020) were opportunistically invited to complete a written version of the survey.
Data collected included demographics, medical and surgical history, therapy duration, type, indication and complications. Climacteric symptoms were assessed using the Greene Climacteric Scale.
Data was obtained for 119 women. The written survey yielded higher response rates ( = 73, 61.3%). Most respondents were 51-60 years old ( = 51 42.9%) and 87.4% ( = 104) were 'White British'. 70 women used estradiol only implants. 30.1%% ( = 34) of patients reported a low Greene Climacteric Scale score (0-5). Subgroup analysis showed prevalence of sexual dysfunction and vasomotor symptoms across ages. There was a lower prevalence of psychological symptoms amongst ≥51 year olds. High satisfaction rates were reported.
Data from a large cohort is presented. Good symptom control, satisfaction and long-term efficacy was demonstrated. This study supports the value of HRT implants for refractory menopause symptoms. A national database of implant users would be a useful tool to record satisfaction scores and adverse events.
对于绝经症状对标准激素替代疗法（HRT）制剂无反应的女性，HRT 植入物提供了一种替代选择。本研究的主要目的是评估女性对植入物治疗的疗效、耐受性、满意度和安全性的看法。
在伯明翰妇女与儿童基金会医院信托基金（Birmingham Women's & Children's Foundation Hospital Trust）进行的单中心服务评估研究。向所有在绝经诊所（1982 年 5 月至 2018 年 12 月）记录接受 HRT 植入物（= 397）的女性（= 397）发布了匿名半结构化调查链接。在诊所就诊的女性（2020 年 6 月至 2020 年 9 月）被随机邀请填写调查的书面版本。
收集的数据包括人口统计学、医疗和手术史、治疗持续时间、类型、适应症和并发症。绝经期症状使用格林绝经量表（Greene Climacteric Scale）进行评估。
获得了 119 名女性的数据。书面调查的回复率更高（= 73，61.3%）。大多数受访者年龄在 51-60 岁（= 51，42.9%），87.4%（= 104）为“白种英国人”。70 名女性仅使用雌二醇植入物。30.1%（= 34）的患者报告格林绝经量表评分低（0-5）。亚组分析显示，各年龄段的性功能障碍和血管舒缩症状的发生率。≥51 岁的患者心理症状发生率较低。报告了高满意度。
提供了大量队列数据。显示出良好的症状控制、满意度和长期疗效。本研究支持 HRT 植入物治疗绝经症状的价值。全国性的植入物使用者数据库将是记录满意度评分和不良事件的有用工具。
